Skip to main content

Table 1 Clinical characteristics of subjects with borderline or less severe PH (mPAP <35 mmHg)

From: Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study

  Untreated borderline or less severe PH Drug-treated borderline or less severe PH P *
No. (male/female) 12(8/4) 12(9/3) 0.66
Age (y.o.) 70.50 ± 7.97 66.92 ± 6.45 0.11
Height (cm) 160.04 ± 10.11 160.87 ± 10.07 0.84
Weight (kg) 62.067 ± 12.17 54.95 ± 12.72 0.25
No. of patients with LTOT 8 7 0.67
ADL including exercise tolerance test
WHO functional class 2.67 ± 0.78 2.83 ± 0.83 0.78
mMRC score 2.42 ± 1.084 2.33 ± 1.44 0.98
SGRQ score
 Symptoms 56.10 ± 22.87 45.78 ± 28.96 0.52
 Activity 61.60 ± 22.35 55.18 ± 33.21 0.98
 Impact 37.53 ± 23.11 34.38 ± 22.18 0.91
 Total 49.42 ± 21.27 43.93 ± 26.41 0.77
SF36
 Physical functioning (PF) 45.83 ± 21.41 60.42 ± 26.41 0.11
 Role physical (RP) 38.58 ± 21.96 51.058 ± 39.16 0.56
 Bodily pain (BP) 72.17 ± 26.30 80.00 ± 25.23 0.45
 General health (GH) 40.67 ± 18.34 46.75 ± 20.067 0.49
 Vitality (VT) 49.34 ± 20.55 58.36 ± 29.23 0.40
 Social functioning (SF) 56.25 ± 26.38 68.75 ± 33.50 0.35
 Role emotional (RE) 62.51 ± 30.048 67.36 ± 37.69 0.52
 Mental health (MH) 63.75 ± 19.67 65. 00 ± 27.88 0.62
Right heart cardiography
 mPAP (mmHg) 20.83 ± 5.75 21.17 ± 7.73 0.93
 mPAPOE (mmHg) 42.67 ± 12.78 42.58 ± 8.87 0.45
 mPAWP (mmHg) 6.83 ± 3.79 6.28 ± 3.57 0.76
 mRVP (mmHg) 14.42 ± 3.58 14.083 ± 6.57 0.31
 mRAP (mmHg) 2.50 ± 1.68 3.00 ± 2.13 0.45
 CO (L/min) 4.80 ± 1.12 5.10 ± 1.27 0.82
 CI (L/min/m2) 2.90 ± 0.56 3.21 ± 0.63 0.38
 PVR (wood) 3.12 ± 1.65 3.022 ± 2.0031 0.95
 PVRI 5.073 ± 2.67 4.58 ± 2.61 1.00
Mixed venous
 PHv 7.39 ± 0.029 7.40 ± 0.026 0.45
 PvCO2 (mmHg) 49.34 ± 6.036 48.15 ± 4.22 0.82
 PvO2 (mmHg) 36.69 ± 3.89 37.55 ± 3.93 0.60
 SVO2 (%) 68.77 ± 5.47 70.53 ± 5.71 0.66
PFT
 %VC (%) 68.34 ± 16.92 69.55 ± 22.62 0.98
 FVC (L) 2.0033 ± 0.57 2.087 ± 0.80 0.86
 %DLCO (%) 30.72 ± 16.0019 27.37 ± 23.76 0.25
TTE
 ET (msec) 299.71 ± 55.95 263.83 ± 36.16 0.18
 PAAcT (msec) 98.67 ± 32.65 94.75 ± 11.65 0.58
 AcT/ET 0.33 ± 0.087 0.37 ± 0.060 0.23
 PEP (msec) 92.71 ± 12.65 87.42 ± 18.62 0.12
 ICT (msec) 17.083 ± 19.96 21.75 ± 21.73 0.70
 IRT (msec) 55.71 ± 45.0023 52.42 ± 36.49 0.95
 ICT + IRT (msec) 87.79 ± 64.54 72.82 ± 46.34 0.69
 TEI index 0.32 ± 0.27 0.30 ± 0.25 0.98
 TAPSE(cm) 2.32 ± 0.47 2.27 ± 0.55 0.75
 Diastolic RA area (cm2) 8.20 ± 3.21 10.64 ± 4.91 0.29
 Diastolic RA major axis (cm) 4.35 ± 2.0037 4.20 ± 2.018 0.66
 Systolic RA area (cm2) 4.74 ± 2.10 5.46 ± 2.60 0.60
 Systolic RA major axis (cm) 2.95 ± 0.99 2.65 ± 0.55 0.25
 Diastolic RV area (cm2) 16.090 ± 6.57 15.39 ± 7.96 0.33
 Diastolic RV major axis (cm) 6.38 ± 1.28 6.22 ± 1.098 0.49
 Systolic RV area (cm2) 9.27 ± 3.47 9.38 ± 4.38 0.64
 Systolic RV major axis (cm) 4.98 ± 1.42 4.95 ± 0.89 0.60
 RVEF (%) 58.91 ± 12.45 51.98 ± 13.29 0.13
Aortic Blood data at rest
 pH 7.41 ± 0.027 7.42 ± 0.022 0.25
 PO2 (mmHg) 76.84 ± 10.091 82.46 ± 7.93 0.11
 Aortic oxygen saturation (%) 95.02 ± 1.55 95.85 ± 1.20 0.12
 BNP (pg/ml) 29.42 ± 20.26 20.76 ± 13.10 0.34
 NT-proBNP (pg/ml) 93.33 ± 60.15 69.67 ± 48.21 0.45
 LA (mg/dl) 11.82 ± 4.082 10.00 ± 3.53 0.33
TMET
 METS 3.55 ± 1.89 3.96 ± 2.54 0.81
Post-TMET Aortic Blood data
 Post-TMET pH 7.34 ± 0.061 7.36 ± 0.069 0.45
 Post-TMET PCO2 (mmHg) 46.94 ± 12.22 43.017 ± 6.75 0.66
 Post-TMET PO2 (mmHg) 54.075 ± 15.93 67.23 ± 14.71 0.18
 Post-TMET oxygen-Sat (%) 80.35 ± 18.077 90.85 ± 4.42 0.14
 Post-TMET BNP (pg/ml) 40.20 ± 34.88 35.62 ± 46.66 0.27
 Post-TMETNT-proBNP (pg/ml) 102.83 ± 67.48 108.67 ± 124.95 0.64
 LA post TMET – LA at rest (mg/dl) 24.68 ± 20.012 22.82 ± 18.88 0.98
 6MWD 246.18 ± 104.27 296.63 ± 128.0090 0.31
Post-6 MW Aortic Blood data
 Post-6MWT pH 7.39 ± 0.021 7.40 ± 0.039 0.15
 Post-6 MW-PCO2 (mmHg) 41.042 ± 8.32 42.64 ± 5.42 0.53
 Post-6 MW-PO2 (mmHg) 77.20 ± 30.98 72.067 ± 15.79 0.91
 Post-TMET Oxygen-Sat (%) 92.58 ± 4.13 90.00 ± 8.35 0.69
 Post-6 MW-BNP (pg/ml) 34.52 ± 25.66 25.080 ± 23.95 0.33
 Post-6 MW-NT-proBNP (pg/ml) 98.50 ± 75.13 80.67 ± 72.41 0.47
 LA post-6 MW – LA at rest (mg/dl) 8.60 ± 8.31 5.42 ± 8.34 0.14
  1. Data presented as mean ± SD
  2. * P value for Mann-Whitney U test to assess the difference between the untreated and drug-treated patients with borderline or less severe PH